Baxter International Inc. (BAX) dropped slightly amid mild profit booking and the last known price was $47.9 per share. The price decreased by -0.01 points or -0.02% which made the investors to buy on weakness. For the latest trading session, the net money flow was recorded at $8.15 million. The total upticks were valued at $46.85 million and the total downticks aggregated to $38.7 million, thereby putting the up/down ratio at 1.21,. The shares has seen a change in the share price of 1.74% on a weekly basis.In a big block trade which occurred today, the total uptick value was $12.02 million and the total downtick value was $3.37, resulting in an up/down ratio of 3.57. The net money flow for the block trade was calculated to be $8.65 million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Baxter International Inc. rose by 4.25% in the last five trading days and 8.48% for the last 4 weeks. Baxter International Inc. is up 1.37% in the last 3-month period. Year-to-Date the stock performance stands at 8.48%. Baxter International Inc. (NYSE:BAX) rose 0.4% or 0.19 points on Wednesday and made its way into the gainers of the day. After trading began at $48.68 the stock was seen hitting $49.29 as a peak level and $46.85 as the lowest level. The stock ended up at $48.1. The daily volume was measured at 6,030,488 shares. The 52-week high of the share price is $50.16 and the 52-week low is $35.54. The company has a market cap of $26,163 million.
Company has reported several Insider transactions to the SEC, on Nov 22, 2016, Kornelis J. Storm (director) sold 4,280 shares at 47.10 per share price.On May 24, 2016, Jose E Almeida (CEO) purchased 11,691 shares at 42.75 per share price.On May 4, 2016, John D Forsyth (director) sold 1,887 shares at 44.38 per share price.
Baxter International Inc Last issued its quarterly earnings results on Feb 1, 2017. The company reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.05. Analyst had a consensus of $0.52. The company had revenue of $2645.00 million for the quarter, compared to analysts expectations of $2650.42 million. The companys revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.
Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The companys products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation centers, nursing homes, doctors offices and by patients, at home, under physician supervision.